Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab

PURPOSE: We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment. METHODS: The medical records of 228 patients who underwent surgical resection and received adjuvant chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, In-Ho, Lee, Ji Eun, Youn, Ho-Joong, Song, Byung Joo, Chae, Byung Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378583/
https://www.ncbi.nlm.nih.gov/pubmed/28382098
http://dx.doi.org/10.4048/jbc.2017.20.1.82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378583/
https://www.ncbi.nlm.nih.gov/pubmed/28382098
http://dx.doi.org/10.4048/jbc.2017.20.1.82

Ejemplares similares